# Becton Dickinson & Co: Form 10-Q for the period ended Jun 30, 2016

- Company: [Becton Dickinson & Co](/companies/bdx.md) (CIK 10795)
- Form: 10-Q
- Filed: 2016-08-04
- Accepted by EDGAR: Aug 4, 2016, 12:06 ET
- Period: 2016-06-30
- Accession: 0001628280-16-018452
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/10795/000162828016018452/bdx0630201610-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/10795/000162828016018452/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-04-01 to 2016-06-30 | $3.20bn | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2015-10-01 to 2016-06-30 | $9.25bn | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2016-04-01 to 2016-06-30 | $1.65bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2015-10-01 to 2016-06-30 | $4.81bn | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months, 2016-04-01 to 2016-06-30 | $207.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2015-10-01 to 2016-06-30 | $575.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2016-04-01 to 2016-06-30 | $728.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2015-10-01 to 2016-06-30 | $2.21bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2016-04-01 to 2016-06-30 | $516.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2015-10-01 to 2016-06-30 | $1.33bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2016-04-01 to 2016-06-30 | $97.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2015-10-01 to 2016-06-30 | $293.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2016-04-01 to 2016-06-30 | $32.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2015-10-01 to 2016-06-30 | $107.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-04-01 to 2016-06-30 | $390.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2015-10-01 to 2016-06-30 | $958.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-04-01 to 2016-06-30 | $1.80 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2015-10-01 to 2016-06-30 | $4.41 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-04-01 to 2016-06-30 | $1.83 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2015-10-01 to 2016-06-30 | $4.51 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2016-04-01 to 2016-06-30 | 217,372,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2015-10-01 to 2016-06-30 | 217,146,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2015-10-01 to 2016-06-30 | $1.85bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2015-10-01 to 2016-06-30 | $405.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2015-10-01 to 2016-06-30 | $421.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | at 2016-06-30 | $1.69bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-06-30 | $6.53bn | us-gaap:AssetsCurrent |
| Total assets | at 2016-06-30 | $26.02bn | us-gaap:Assets |
| Current liabilities | at 2016-06-30 | $4.22bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2016-06-30 | $10.56bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2016-06-30 | $1.35bn | us-gaap:DebtCurrent |
| Shareholders' equity | at 2016-06-30 | $8.03bn | us-gaap:StockholdersEquity |
| Shares outstanding | at 2016-06-30 | 212,925,842 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 45,663 characters.

The following commentary should be read in conjunction with the condensed consolidated financial statements and accompanying notes. Within the tables presented throughout this discussion, certain columns may not add due to the use of rounded numbers for disclosure purposes. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

### Company Overview

Becton, Dickinson and Company (“BD”) is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company's organizational structure is based upon two principal business segments, BD Medical (“Medical”) and BD Life Sciences (“Life Sciences”).

BD’s products are manufactured and sold worldwide. Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives. We organize our operations outside the United States as follows: Europe; EMA (which includes the Commonwealth of Independent States, the Middle East and Africa); Greater Asia (which includes Japan and Asia Pacific); Latin America (which includes Mexico, Central America, the Caribbean, and South America); and Canada. We continue to pursue growth opportunities in emerging markets, which include the following geographic regions: Eastern Europe, the Middle East, Africa, Latin America and certain countries within Asia Pacific. We are primarily focused on certain countries whose healthcare systems are expanding, in particular, China and India.

### Acquisition of CareFusion

On March 17, 2015, BD acquired a 100% interest in CareFusion Corporation ("CareFusion"). CareFusion’s operating results were included in BD’s consolidated results of operations beginning on April 1, 2015 and as such, the consolidated results of operations for the first six months of the nine-month period ended June 30, 2015 referenced in the commentary provided further below did not include CareFusion's results. CareFusion operates as part of our Medical segment.

### Overview of Financial Results and Financial Condition

For the three months ended June 30, 2016, revenues of $3.198 billion increased 2.5% from the prior year period. The increase in revenue was attributable to volume growth of 3.5%, which includes a net unfavorable impact of 0.5% resulting from the termination of a distribution agreement in the Respiratory Solutions unit and, to a lesser extent, the impact of purchase accounting on deferred revenue related to the acquisition of CareFusion. Revenue growth attributable to volume was offset by approximately 0.9% of foreign currency translation. Price was not a material driver of growth for the period and accounted for approximately 0.1% of growth.

The current-year period’s volume impact reflected the following:

- Third quarter Medical segment sales were driven by growth in the Medication Management Solutions, Diabetes Care and Medication and Procedural Solutions units. Third quarter revenues in the Respiratory Solutions unit were unfavorably impacted by the termination of a distribution contract, as noted above.
- Life Sciences segment sales in the third quarter primarily reflected growth in the Diagnostic Systems and Preanalytical Systems units.
- Worldwide sales of safety-engineered products reflected growth that was attributable to both segments. Third quarter sales in the United States of safety-engineered devices of $450 million increased 5.3% and third quarter international sales of safety-engineered devices of $334 million grew 10.8% over the prior year’s period, inclusive of an estimated 3.1% unfavorable impact due to foreign currency translation.

We continue to invest in research and development, geographic expansion, and new product promotions to drive further revenue and profit growth. Our ability to sustain our long-term growth will depend on a number of factors, including our ability to expand our core business (including geographical expansion), develop innovative new products, and continue to improve operating efficiency and organizational effectiveness, including through the integration of CareFusion. While the economic environment for the healthcare industry has stabilized, pricing pressures continue for some of our products. Healthcare utilization and research spending has stabilized and slightly improved in the United States; however, any destabilization in the future could adversely impact our U.S. businesses. Additionally, macroeconomic challenges in Europe continue to constrain healthcare utilization, although we currently view the environment as stable. In emerging markets, the Company’s growth is dependent primarily on government funding for healthcare systems.

Our financial position remains strong, with cash flows from operating activities totaling $1.854 billion in the first nine months of fiscal year 2016. At June 30, 2016, we had $1.7 billion in cash and equivalents and short-term investments. We continued to return value to our shareholders in the form of dividends. During the first nine months of fiscal year 2016, we paid cash dividends of $421 million. No shares were repurchased during the first nine months of fiscal year 2016.

Each reporting period, we face currency exposure that arises from translating the results of our worldwide operations to the U.S. dollar at exchange rates that fluctuate from the beginning of such period. The ongoing relative strength of the U.S. dollar resulted in an unfavorable foreign currency translation impact to our revenue growth during the quarter. We evaluate our results of operations on both a reported and a foreign currency-neutral basis, which excludes the impact of fluctuations in foreign currency exchange rates. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of results on a foreign currency-neutral basis in addition to reported results helps improve investors’ ability to understand our operating results and evaluate our performance in comparison to prior periods. Foreign currency-neutral ("FXN") information compares results between periods as if exchange rates had remained constant period-over-period. We use results on a foreign currency-neutral basis as one measure to evaluate our performance. We calculate foreign currency-neutral percentages by converting our current-period local currency financial results using the prior-period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. These results should be considered in addition to, not as a substitute for, results reported in accordance with U.S. generally accepted accounting principles ("GAAP"). Results on a foreign currency-neutral basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with U.S. GAAP.

### Results of Operations

### Revenues

#### Medical Segment

The following summarizes third quarter Medical revenues by organizational unit, as well as third quarter Medical sales of safety-engineered products:

| (Millions of dollars) | Three months ended June 30, 2016 | 2015 | Total Change | Estimated FX Impact | FXN Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Medication and Procedural Solutions | $851 | $848 | 0.3% | (1.8)% | 2.1% |
| Medication Management Solutions | 587 | 554 | 5.9% | (0.3)% | 6.2% |
| Diabetes Care | 258 | 245 | 5.5% | (1.1)% | 6.6% |
| Pharmaceutical Systems | 342 | 333 | 2.5% | 1.0% | 1.5% |
| Respiratory Solutions | 199 | 232 | (13.9)% | (0.2)% | (13.7)% |
| Deferred revenue adjustment (A) | (2) | (13) | (82.9)% | —% | (82.9)% |
| Total Medical Revenues | $2,235 | $2,199 | 1.6% | (0.8)% | 2.4% |
| Medical segment safety-engineered products | $493 | $454 | 8.6% | (1.0)% | 9.6% |

(A) In accordance with U.S. GAAP business combination accounting rules, CareFusion’s deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date. The deferred revenue adjustment represents the amortization of this write-down which primarily relates to software maintenance contracts in the United States. Revenues for these contracts is typically deferred and recognized over the term of the contracts.

Third quarter revenues in the Medication and Procedural Solutions unit reflected growth in sales of infusion therapy and safety-engineered products. The Medication Management Solutions unit's revenue growth reflected installations of dispensing capital and sales of infusion systems. The Diabetes Care unit's revenue growth in the quarter was driven by sales of pen needles. Third quarter revenue growth in the Pharmaceutical Systems unit reflected growth in sales of self-injection systems and safety-engineered products. The timing, in the second quarter of the current fiscal year, of earlier than anticipated customer orders in the Pharmaceutical Systems and capital placements in the Respiratory Solutions unit unfavorably impacted third quarter revenues as compared to the prior-year period. Third quarter revenues, as compared to the prior year, in the Respiratory Solutions unit were also unfavorably impacted by the termination of a distribution contract, as previously discussed.

Medical segment revenues and sales of safety-engineered products for the nine-month period were as follows:

| (Millions of dollars) | Nine months ended June 30, 2016 | 2015 | Total Change | Estimated FX Impact | FXN Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Total Medical Revenues | $6,420 | $4,377 | 46.7% | (4.2)% | 50.9% |
| Medical segment safety-engineered products | $1,425 | $1,031 | 38.2% | (4.0)% | 42.2% |

Medical segment operating income for the three-month and nine-month periods were as follows:

| (Millions of dollars) | Three months ended June 30, 2016 | 2015 | Nine months ended June 30, 2016 | 2015 |
| --- | ---: | ---: | ---: | ---: |
| Medical segment operating income | $571 | $483 | $1,549 | $1,115 |
| Segment operating income as % of Medical revenues | 25.5% | 22.0% | 24.1% | 25.5% |

The Medical segment's operating income is driven by its performance with respect to gross profit margin and operating expenses. Gross profit margin was higher in the current quarter as compared with the third quarter of 2015 primarily due to lower manufacturing costs resulting from continuous improvement projects improving the efficiency of our operations and lower raw material costs, partially offset by unfavorable foreign currency translation. Selling and administrative expense for the third quarter of fiscal year 2016 was lower primarily due to the suspension of the medical device excise tax imposed under the U.S. Patient Protection Affordable Care Act. Research and development expenses for the quarter increased $18 million, or 19% above the prior year’s period, which reflected increased investment in new products and platforms.

#### Life Sciences Segment

The following is a summary of third quarter Life Sciences revenues by organizational unit, as well as third quarter Life Sciences sales of safety-engineered products:

| (Millions of dollars) | Three months ended June 30, 2016 | 2015 | Total Change | Estimated FX Impact | FXN Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Preanalytical Systems | $366 | $349 | 4.8% | (1.8)% | 6.6% |
| Diagnostic Systems | 327 | 302 | 8.2% | (1.3)% | 9.5% |
| Biosciences | 270 | 269 | 0.4% | (0.8)% | 1.2% |
| Total Life Sciences Revenues | $963 | $921 | 4.6% | (1.4)% | 6.0% |
| Life Sciences segment safety-engineered products | $291 | $275 | 5.9% | (1.7)% | 7.6% |

The Preanalytical Systems unit's revenue growth was driven by U.S. and international sales of safety-engineered products. Growth in the Diagnostic Systems unit was driven by core microbiology sales, including *BD Kiestra*TM installations, and sales of molecular diagnostic platforms during the quarter. The Biosciences unit’s third quarter revenues reflected pressure on sales of HIV-related clinical products in Africa and delayed government funding, primarily in Western Europe and Japan, offset by growth in sales of research instruments in the United States and global sales of research reagents.

Life Sciences segment total revenues and sales of safety-engineered products for the nine-month period were as follows:

| (Millions of dollars) | Nine months ended June 30, 2016 | 2015 | Total Change | Estimated FX Impact | FXN Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| Total Life Sciences Revenues | $2,832 | $2,845 | (0.5)% | (4.2)% | 3.7% |
| Life Sciences segment safety-engineered products | $829 | $822 | 0.9% | (4.5)% | 5.4% |

Life Sciences segment operating income for the three-month and nine-month periods were as follows:

| (Millions of dollars) | Three months ended June 30, 2016 | 2015 | Nine months ended June 30, 2016 | 2015 |
| --- | ---: | ---: | ---: | ---: |
| Life Sciences segment operating income | $200 | $197 | $604 | $610 |
| Segment operating income as % of Life Sciences revenues | 20.8% | 21.4% | 21.3% | 21.4% |

The Life Sciences segment's operating income is driven by its performance with respect to gross profit margin and operating expenses. Gross profit margin in the third quarter of fiscal year 2016 was lower compared with the third quarter of 2015 primarily due to the unfavorable impact of foreign currency translation, partially offset by lower manufacturing costs resulting from continuous improvement projects improving the efficiency of our operations. Selling and administrative expense as a percentage of Life Sciences revenues in the third quarter of 2016 was also lower compared to the prior-year period primarily due to the suspension of the medical device excise tax. Research and development expense in the third quarter of 2016 increased by $7 million, or 10% above the prior year’s period, which reflected increased investment in new products and platforms.

#### Geographic Revenues

BD’s worldwide third quarter revenues by geography were as follows:

| (Millions of dollars) | Three months ended June 30, 2016 | 2015 | Total Change | Estimated FX Impact | FXN Change |
| --- | ---: | ---: | ---: | ---: | ---: |
| United States | $1,735 | $1,693 | 2.5% | — | 2.5% |
| International | 1,463 | 1,427 | 2.5% | (2.1)% | 4.6% |
| Total Revenues | $3,198 | $3,120 | 2.5% | (0.9)% | 3.4% |

U.S. revenues reflected growth from both segments. The Medical segment's U.S. revenues reflected growth in sales of the Diabetes Care unit's pen needles as well as growth from the Medication Management Solutions unit's dispensing equipment and infusion systems. U.S. revenue growth in the Medical segment also reflected sales of self-injection systems and safety-engineered products in the Pharmaceutical Systems unit. U.S. growth in the Respiratory Solutions unit was negatively impacted by the termination of a distribution contract, as previously discussed. U.S. Life Sciences revenue growth in the third quarter of fiscal year 2016 was driven by sales of the Preanalytical Systems unit's products as well as the Diagnostic Systems unit's blood culture and molecular diagnostic platforms. U.S. Life Sciences revenue growth also reflected research instrument placements and research reagent sales in the Biosciences unit.

The Medical segment's international revenue growth was driven by sales in China and by sales of safety-engineered products. The Medication Management Solutions unit's international revenue growth was driven by dispensing equipment installations. International revenue growth in the Medical segment was negatively impacted by the timing of orders in the Pharmaceutical Systems unit and by the timing of the Respiratory Solutions unit's capital placements, as previously discussed. The Life Sciences segment's third quarter international revenue growth reflected the Diagnostic Systems unit's *BD KiestraTM* installations in Western Europe as well as sales of core microbiology products and cervical cancer-related product offerings. The Preanalytical Systems unit's international revenue growth was driven by sales of safety-engineered products in all regions. International revenue growth in the Biosciences unit was negatively impacted by the previously discussed funding delays and pressure on sales of HIV-related clinical products in Africa.

Effective October 1, 2015, we changed the composition of countries that we define as emerging markets within the Asia Pacific region. On this redefined basis, emerging market revenues for the third quarter were $485 million, compared with $491 million in the prior year’s quarter, and included an estimated $31 million unfavorable impact due to foreign currency translation. Third quarter revenue growth in emerging markets reflected growth in China and Latin America, partially offset by declines in the Middle East and Africa.

### Specified Items

Reflected in the financial results for the three and nine-month periods of fiscal years 2016 and 2015 are the following specified items:

| (Millions of dollars) | Three months ended June 30, 2016 | 2015 | Nine months ended June 30, 2016 | 2015 |
| --- | ---: | ---: | ---: | ---: |
| Financing costs (A) | $— | $5 | $— | $107 |
| Transaction costs (A) | 7 | 9 | 7 | 52 |
| Integration costs (A) | 40 | 24 | 115 | 55 |
| Restructuring costs (A) | 49 | 75 | 198 | 136 |
| Purchase accounting adjustments (B) | 127 | 439 | 395 | 466 |
| Pension settlement charges | 3 | — | 3 | — |
| Other (C) | — | (5) | — | 7 |
| Total specified items | 226 | 548 | 718 | 824 |
| Tax impact of specified items | 106 | 169 | 270 | 277 |
| After-tax impact of specified items | $120 | $379 | $449 | $547 |

(A) Represents financing, transaction, integration and restructuring costs substantially associated with the CareFusion acquisition and portfolio rationalization. The financing costs were recorded in *Interest expense*. The transaction, integration and restructuring costs were recorded in *Acquisitions and other restructurings.*

(B) Primarily represents non-cash amortization expense associated with acquisition-related identifiable intangible assets. BD’s amortization expense is primarily recorded in *Costs of products sold*. The adjustment in the nine-month period of fiscal year 2016 also included a net decrease in the fair value of certain contingent consideration liabilities of $26 million. The adjustments in the three and nine-month periods of fiscal year 2015 also included a fair value step-up adjustment of $281 million recorded relative to CareFusion’s inventory on the acquisition date. The adjustment for the nine months ended June 30, 2015 additionally reflected a pre-tax acquisition-date accounting gain of $9 million on a previously held investment.

(C) The adjustments in the three and nine-month periods ended June 30, 2015 include a decrease to the liability for employee termination costs recorded relative to workforce reduction actions taken in the fourth quarter of fiscal year 2014. The adjustment in the nine-month period additionally includes a charge for plaintiff attorneys’ fees, recorded in *Selling and administrative expense,* associated with the antitrust and false advertising lawsuit RTI filed against BD. For further discussion, refer to Note 5 in the Notes to Condensed Consolidated Financial Statements.

### Gross Profit Margin

Gross profit margin for the three and nine-month periods of fiscal year 2016 compared with the prior-year periods in 2015 reflected the following impacts:

|  | Three-month period | Nine-month period |
| --- | ---: | ---: |
| **June 30, 2015 gross profit margin %** | 37.6% | 45.2% |
| CareFusion acquisition-related asset depreciation and amortization | 9.4% | 0.4% |
| Operating performance | 2.0% | 3.0% |
| Foreign currency translation | (0.6)% | (0.6)% |
| **June 30, 2016 gross profit margin %** | 48.4% | 48.0% |

Gross profit margin in the current-year periods benefited from a favorable comparison to the prior-year periods, which reflected the recognition of a fair value step-up adjustment recorded relative to CareFusion’s inventory on the acquisition date, as previously discussed. The operating performance impacts for the current year's quarter and nine-month period primarily reflected lower manufacturing costs resulting from continuous improvement projects improving the efficiency of our operations, as well as lower raw material costs.

### Operating Expenses

A summary of operating expenses for the three and nine months ended June 30, 2016 and 2015 is as follows:

| (Millions of dollars) | Three months ended June 30, 2016 | 2015 | Increase (decrease) in basis points 2016 | Nine months ended June 30, 2015 |  | Increase (decrease) in basis points |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Selling and administrative expense | $728 | $751 |  | $2,209 | $1,806 |  |
| % of revenues | 22.8% | 24.1% | (130) | 23.9% | 25.0% | (110) |
| Research and development expense | $207 | $178 |  | $575 | $436 |  |
| % of revenues | 6.5% | 5.7% | 80 | 6.2% | 6.0% | 20 |
| Acquisitions and other restructurings | $96 | $108 |  | $321 | $244 |  |

#### Selling and administrative expense

Selling and administrative expense as a percentage of revenues in the current year’s three and nine-month periods reflected cost synergies resulting from the CareFusion acquisition as well as the benefit from suspension of the medical device excise tax, as previously discussed. Selling and administrative expense as a percentage of revenues in the current year’s nine-month period also reflected favorable foreign currency translation, partially offset by the unfavorable impact of depreciation recorded in the first half of the fiscal year relating to fixed assets acquired in the CareFusion acquisition.

#### Research and development expense

The increase in research and development expense for the three-month period of fiscal year 2016 compared with the prior-year period in 2015 primarily reflected the timing of project spending and an increase in the number of ongoing projects. Research and development expense for nine-month period of fiscal year 2016 was also higher compared with the prior-year period due to the inclusion of CareFusion’s research and development expenses in the Company's results during the first half of fiscal year 2016.

#### Acquisitions and other restructurings

Costs relating to acquisitions and other restructurings in the three and nine-month periods represented transaction, integration and restructuring costs substantially associated with the CareFusion acquisition and portfolio rationalization. The transaction and integration costs specifically included advisory, legal, and other costs substantially incurred in connection with the CareFusion acquisition. For further disclosures regarding the restructuring costs, refer to Note 11 in the Notes to Condensed Consolidated Financial Statements.

### Net Interest Expense

The components of net interest expense for the three and nine-month periods were as follows:

| (Millions of dollars) | Three months ended June 30, 2016 | 2015 | Nine months ended June 30, 2016 | 2015 |
| --- | ---: | ---: | ---: | ---: |
| Interest expense | $(97) | $(105) | $(293) | $(272) |
| Interest income | 5 | 2 | 14 | 20 |
| Net interest expense | $(92) | $(103) | $(279) | $(252) |

The decrease in interest expense for the three-month period of fiscal year 2016 compared with the prior year's period primarily reflected a favorable comparison to the prior-year period, which included fees incurred to exchange CareFusion notes assumed in the acquisition for BD notes. The increase in interest expense for the nine-month period of fiscal year 2016 reflected increased financing costs, recorded in the first half of fiscal year 2016, associated with the CareFusion acquisition, partially offset by favorable amortization of the acquisition-date fair value-step, recorded in the first half of fiscal year 2016, on CareFusion’s long-term debt. This net year-to-date increase in financing costs relating to the CareFusion acquisition was partially offset by the prior-year impact of fees incurred to exchange CareFusion's notes, as discussed above, and commitment fees incurred for a bridge loan facility that was terminated in March 2015.

The increase in interest income for the three-month period of fiscal year 2016 compared with the prior year’s period primarily reflected the realization of investment gains on assets related to our deferred compensation plans, compared with the realization of losses in the prior year's quarter. The decrease in interest income for the nine-month period of fiscal year 2016 reflected lower cash levels outside of the United States, partially offset by higher investment gains on assets related to our deferred compensation plans. The offsetting movements in the deferred compensation plan liability were recorded in *Selling and administrative expense.*

### Income Taxes

The income tax rates for the three and nine-month periods are provided below. The tax benefits of the specified items shown earlier reduced the current and prior-year periods' income tax rates, as the tax benefits on these specified items were primarily incurred in higher tax jurisdictions. The income tax rates for the current-year periods are higher compared with the prior periods' rates as the specified charges incurred in the current-year periods were lower compared with charges incurred in the prior-year periods.

|  | Three months ended June 30, 2016 | 2015 | Nine months ended June 30, 2016 | 2015 |
| --- | ---: | ---: | ---: | ---: |
| Effective income tax rate | 7.6% | (60.0)% | 10.1% | 6.4% |
| Favorable impact, in basis points, from tax benefits of specified items | 1,370 | 8,480 | 1,100 | 1,630 |

### Net Income and Diluted Earnings per Share

Net Income and Diluted Earnings per Share for the three and nine-month periods were as follows:

|  | Three months ended June 30, 2016 | 2015 | Nine months ended June 30, 2016 | 2015 |
| --- | ---: | ---: | ---: | ---: |
| Net Income (Millions of dollars) | $390 | $62 | $958 | $514 |
| Diluted Earnings per Share | $1.80 | $0.29 | $4.41 | $2.52 |
| Unfavorable impact-specified items | $(0.55) | $(1.76) | $(2.07) | $(2.68) |
| Unfavorable impact-foreign currency translation | $(0.10) |  | $(0.51) |  |

### Liquidity and Capital Resources

The following table summarizes our consolidated statement of cash flows:

| (Millions of dollars) Net cash provided by (used for) | Nine months ended June 30, 2016 | 2015 |
| --- | ---: | ---: |
| Operating activities | $1,854 | $1,052 |
| Investing activities | $(318) | $(8,003) |
| Financing activities | $(1,276) | $6,667 |

### Net Cash Flows from Operating Activities

Cash generated from operations, along with available cash and cash equivalents, is expected to be sufficient to fund our normal operating needs for the remainder of fiscal year 2016. Normal operating needs in fiscal year 2016 include working capital, capital expenditures, and cash dividends. The change in net cash provided by operating activities was primarily attributable to income from continuing operations, as adjusted for depreciation and amortization and other non-cash items. The current period change in operating assets and liabilities was a net use of cash and primarily reflected higher levels of accounts receivables and lower levels of accounts payable and accrued expenses, partially offset by lower levels of prepaid expenses and financing receivables. Net cash provided by operating activities in the first nine months of fiscal year 2015 was reduced by a discretionary cash contribution of $40 million to fund our pension obligation.

### Net Cash Flows from Investing Activities

Capital expenditures were $405 million in the first nine-months of fiscal year 2016 compared with $387 million in the prior-year period. Net cash used for investing activities in the current-year period reflected $158 million of proceeds from the sales of non-core assets. Net cash used for investing activities in the prior-year period reflected cash outflows of $8.3 billion related to our acquisition of CareFusion and other smaller acquisitions occurring in the prior-year period. These cash outflows in the prior-year period were partially offset by sales of investments of $837 million due to the maturities of time deposits in Europe, Latin America and Asia Pacific.

### Net Cash Flows from Financing Activities

Net cash used for financing activities in the first nine-months of fiscal year 2016 included a net $150 million reduction of our commercial paper program balance and the third quarter repayment of $750 million of floating rate notes due on June 15, 2016. Net cash provided by financing activities in the prior-year period included the proceeds from $6.2 billion of notes issued in December 2014 as well as $850 million total proceeds from net borrowings under commercial paper programs and a term loan facility. These proceeds were used to finance the completion of our acquisition of CareFusion in March 2015.

#### Debt-related Activities

Certain measures relating to our total debt were as follows:

| (Millions of dollars) | June 30, 2016 | September 30, 2015 |
| --- | ---: | ---: |
| Total debt | $11,913 | $12,822 |
| Short-term debt as a percentage of total debt | 11.3% | 11.3% |
| Weighted average cost of total debt | 3.5% | 3.3% |
| Total debt as a percentage of total capital\* | 56.0% | 59.4% |

\* Represents shareholders’ equity, net non-current deferred income tax liabilities, and debt.

The ratio of short-term debt as a percentage of total debt at June 30, 2016 reflected the reclassifications, from long-term debt to short-term debt, of $500 million of 1.75% notes due on November 8, 2016 and $300 million of 1.450% notes due May 15, 2017, offset by the repayment of $750 million of floating rate notes, as previously discussed. The ratio of debt as a percentage of total capital at September 30, 2015 reflects adjustments to the condensed consolidated balance sheet resulting from our adoption of revised presentation requirements relating to deferred taxes. Additional information regarding this adoption is provided in Note 2 in the Notes to Condensed Consolidated Financial Statements.

### Cash and Short-term Investments

At June 30, 2016, total worldwide cash and short-term investments were approximately $1.70 billion, of which $1.25 billion was held in jurisdictions outside of the United States. We regularly review the amount of cash and short-term investments held outside the United States and currently intend to use such amounts to fund our international operations and their growth initiatives. In addition, if these amounts were repatriated from foreign jurisdictions to the United States, there could be adverse tax consequences.

### Credit Facilities

We have in place a commercial paper borrowing program which is available to meet our short-term financing needs, including working capital requirements. In February 2016, we increased the size of this program by $500 million so that it allows us to issue a maximum of $1.5 billion in notes. Borrowings outstanding under this program were $550 million at June 30, 2016, which reflected a net reduction of $150 million from our outstanding balance of commercial paper borrowings at September 30, 2015, as previously discussed.

In January 2016, we replaced an existing $1 billion syndicated credit facility with a $1.5 billion syndicated credit facility that has an expiration date of January 2021. There were no borrowings outstanding under this credit facility at June 30, 2016. The credit facility, under which we may issue up to $100 million in letters of credit, provides backup support for our commercial paper program and can also be used for other general corporate purposes. It includes a provision that enables BD, subject to additional commitments made by the lenders, to access up to an additional $500 million in financing through the facility for a maximum aggregate commitment of $2 billion. The credit facility includes a single financial covenant that requires BD to maintain an interest expense coverage ratio of not less than 5-to-1 for the most recent four consecutive fiscal quarters. We were in compliance with this covenant as of June 30, 2016. We also have informal lines of credit outside the United States.

### Concentrations of Credit Risk

We continually evaluate our accounts receivables for potential collection risks, particularly those resulting from sales to government-owned or government-supported healthcare facilities in certain countries, as payment may be dependent upon the financial stability and creditworthiness of those countries’ national economies. We continually evaluate all governmental receivables for potential collection risks associated with the availability of government funding and reimbursement practices. We believe the current reserves related to all governmental receivables are adequate and that these receivables will not have a material adverse impact on our financial position or liquidity.

### Cautionary Statement Regarding Forward-Looking Statements

BD and its representatives may from time to time make certain forward-looking statements in publicly released materials, both written and oral, including statements contained in filings with the Securities and Exchange Commission, press releases, and our reports to shareholders. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance, as well as our strategy for growth, product development, regulatory approvals, market position and expenditures. All statements that address operating performance or events or developments that we expect or anticipate will occur in the future – including statements relating to volume growth, sales and earnings per share growth, cash flows or uses, and statements expressing views about future operating results – are forward-looking statements.

Forward-looking statements are based on our current expectations of future events. The forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events, developments and operating performance, and speak only as of their dates. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements. Furthermore, we undertake no obligation to update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events and developments or otherwise, except as required by applicable law or regulations.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements. For further discussion of certain of these factors, see Item 1A. Risk Factors in our 2015 Annual Report on Form 10-K.

- Weakness in the global economy and financial markets, and the potential adverse effect on the cost of operating our business, the demand for our products and services, the prices for our products and services due to increases in pricing pressure, or our ability to produce our products, including the impact on developing countries.
- Deficit reduction efforts or other adverse changes in the availability of government funding for healthcare and research that could further weaken demand for our products and result in additional pricing pressures, as well as create potential collection risks associated with such sales.
- Risks relating to our acquisition of CareFusion, including our ability to successfully combine and integrate the CareFusion operations in order to obtain the anticipated benefits and costs savings from the transaction, and the significant additional indebtedness we incurred in connection with the financing of the acquisition and the impact this increased indebtedness may have on our ability to operate the combined company.
- The consequences of the Patient Protection and Affordable Care Act in the United States, which implemented an excise tax on U.S. sales of certain medical devices (which has been suspended until January 1, 2018), and which could result in reduced demand for our products, increased pricing pressures or otherwise adversely affect our business.
- Future healthcare reform in the countries in which we do business that may involve changes in government pricing and reimbursement policies or other cost containment reforms.
- Changes in domestic and foreign healthcare industry practices that result in a reduction in procedures using our products or increased pricing pressures, including the continued consolidation among healthcare providers and trends toward managed care and healthcare cost containment. For example, changes to guidelines providing for increased cervical cancer screening intervals has and may continue to negatively impact sales of our Women’s Health and Cancer platform.
- Changes in reimbursement practices of private third-party payers.
- Our ability to penetrate or expand our operations in emerging markets, which depends on local economic and political conditions, and how well we are able to acquire or form strategic business alliances with local companies and make necessary infrastructure enhancements to production facilities and distribution networks. Our international operations also increase our compliance risks, including risks under the Foreign Corrupt Practices Act and other anti-corruption laws.
- Political conditions in international markets, including civil unrest, terrorist activity, governmental changes, trade barriers, restrictions on the ability to transfer capital across borders and expropriation of assets by a government.
- Security breaches of our computer and communications systems or our products, including computer viruses, “hacking” and “cyber-attacks,” which could impair our ability to conduct business, result in the loss of BD trade secrets or otherwise compromise sensitive information of BD or its customers, suppliers and other business partners, or of customers' patients, or result in product efficacy or safety concerns.
- Fluctuations in the cost and availability of oil-based resins and other raw materials, as well as certain components, the ability to maintain favorable supplier arrangements and relationships (particularly with respect to sole-source suppliers), and the potential adverse effects of any disruption in the availability of such items.
- Regional, national and foreign economic factors, including inflation, deflation, fluctuations in interest rates and, in particular, foreign currency exchange rates, and the potential effect on our revenues, expenses, margins and credit ratings. The June 23, 2016 advisory referendum by British voters to exit the European Union (“EU”) has created uncertainties affecting business operations in the United Kingdom (“UK”) and the EU. Following the vote, there was a significant decline in the value of the British pound compared to the U.S. dollar, and there may be continued volatility in exchange rates and economic conditions as the UK negotiates its exit from the EU. Until the terms and timing of the UK’s exit from the EU are determined, it is difficult to predict its impact. It is possible that the referendum and proposed withdrawal could, among other things, affect the legal and regulatory schemes to which our businesses are subject, impact trade between the UK and the EU and other parties and create economic uncertainty in the region.
- New or changing laws and regulations affecting our domestic and foreign operations, or changes in enforcement practices, including laws relating to trade, monetary and fiscal policies, taxation (including tax reforms that could adversely impact multinational corporations), sales practices, environmental protection, price controls and licensing and regulatory requirements for new products and products in the postmarketing phase. In particular, the U.S. and other countries may impose new requirements regarding registration, labeling or prohibited materials that may require us to re-register products already on the market or otherwise impact our ability to market our products. Environmental laws, particularly with respect to the emission of greenhouse gases, are also becoming more stringent throughout the world, which may increase our costs of operations or necessitate changes in our manufacturing plants or processes or those of our suppliers, or result in liability to BD.
- Product efficacy or safety concerns regarding our products resulting in product recalls, regulatory action on the part of the U.S. Food and Drug Administration (FDA) or foreign counterparts, declining sales and product liability claims, particularly in light of the current regulatory environment, in which there has been increased enforcement activity by the FDA. As a result of the CareFusion acquisition, we are operating under a consent decree with the FDA relating to our U.S. infusion pump business. The consent decree authorizes the FDA, in the event of any violations in the future, to order us to cease manufacturing and distributing products, recall products or take other actions, and we may be required to pay significant monetary damages if we fail to comply with any provision of the consent decree.
- Competitive factors that could adversely affect our operations, including new product introductions (for example, new forms of drug delivery) by our current or future competitors, increased pricing pressure due to the impact of low-cost manufacturers as certain competitors have established manufacturing sites or have contracted with suppliers in low-cost manufacturing locations as a means to lower their costs, patents attained by competitors (particularly as patents on our products expire), and new entrants into our markets.
- The effects of events that adversely impact our ability to manufacture our products (particularly where production of a product line is concentrated in one or more plants) or our ability to source materials or components from suppliers (including sole-source suppliers) that are needed for such manufacturing, including pandemics, natural disasters, or environmental factors.
- Difficulties inherent in product development, including the potential inability to successfully continue technological innovation, complete clinical trials, obtain regulatory approvals in the United States and abroad, obtain intellectual property protection for our products, obtain coverage and adequate reimbursement for new products, or gain and maintain market approval of products, as well as the possibility of infringement claims by competitors with respect to patents or other intellectual property rights, all of which can preclude or delay commercialization of a product. Delays in obtaining necessary approvals or clearances from the FDA or other regulatory agencies or changes in the regulatory process may also delay product launches and increase development costs.
- Fluctuations in the demand for products we sell to pharmaceutical companies that are used to manufacture, or are sold with, the products of such companies, as a result of funding constraints, consolidation or otherwise.
- Fluctuations in university or U.S. and international governmental funding and policies for life sciences research.
- Our ability to achieve our projected level or mix of product sales, as our earnings forecasts are based on projected sales volumes and pricing of many product types, some of which are more profitable than others.
- Pending and potential future litigation or other proceedings adverse to BD, including antitrust, product liability, environmental and patent infringement, and the availability or collectability of insurance relating to any such claims.
- The effect of adverse media exposure or other publicity regarding BD’s business or operations, including the effect on BD’s reputation or demand for its products.
- The effect of market fluctuations on the value of assets in BD’s pension plans and on actuarial interest rate and asset return assumptions, which could require BD to make additional contributions to the plans or increase our pension plan expense.
- The impact of business combinations, including any volatility in earnings relating to acquired in-process research and development assets, and our ability to successfully integrate any business we may acquire.
- Our ability to obtain the anticipated benefits of restructuring programs, if any, that we may undertake.
- Issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission.

The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties.

## Controls and procedures

As filed, 1,019 characters.

An evaluation was carried out by BD’s management, with the participation of BD’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of BD’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of June 30, 2016. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the design and operation of these disclosure controls and procedures were, as of the end of the period covered by this report, effective and designed to ensure that material information relating to BD and its consolidated subsidiaries would be made known to them by others within these entities. There were no changes in our internal control over financial reporting during the fiscal quarter ended June 30, 2016 identified in connection with the above-referenced evaluation that have materially affected, or are reasonably likely to materially affect, BD’s internal control over financial reporting.

## Risk factors

As filed, 172 characters.

There were no material changes in the risk factors previously disclosed in Part I, Item 1A, of our 2015 Annual Report on Form 10-K during the period covered by this report.

Filed Aug 4, 2016.
Source: SEC EDGAR, the filing index for accession 0001628280-16-018452. Last ingested by Listed: Nov 11, 2026, 03:43 ET. No prices; not investment advice.
